Acurx Pharmaceuticals (NASDAQ:ACXP) Announces Earnings Results

Acurx Pharmaceuticals (NASDAQ:ACXP) posted its quarterly earnings results on Thursday. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.11), FiscalAI reports.

Here are the key takeaways from Acurx Pharmaceuticals’ conference call:

• Acurx began enrolling patients in its fully funded, 20-patient PATHFINDER trial for multiply recurrent C. difficile infection in September. Management expects an enrollment update after completion, potentially in the second half of 2027.
• The FDA is open to further discussion of whether data from PATHFINDER and the planned ASPIRE Phase III study could support an NDA; it has not confirmed an approval pathway. Depending on PATHFINDER results and funding, Acurx may pursue a follow-on recurrent-infection trial under the LPAD pathway, while continuing to consider ASPIRE.
• Acurx ended the quarter with $9.7 million in cash and said it has 12 months of funds, which management believes can cover PATHFINDER if enrollment is completed by the third quarter of 2027. The company may need additional financing through equity or other sources, and reported a quarterly net loss of $2.6 million, up from $2.0 million a year earlier.
• Management said partnering discussions are active but none are at a stage for public disclosure, and it is pursuing grants and other funding for its Phase III program. The company’s proposed PATHFINDER 2 could involve about 350 patients and take 18–24 months to enroll, but its design, cost, and regulatory prospects remain uncertain.

Acurx Pharmaceuticals Stock Down 2.4%

Shares of ACXP stock traded down $0.03 on Thursday, hitting $1.00. The company had a trading volume of 111,328 shares, compared to its average volume of 962,296. The firm has a market cap of $5.59 million, a P/E ratio of -0.37 and a beta of -2.08. The company has a 50-day moving average price of $1.23 and a 200-day moving average price of $1.92. Acurx Pharmaceuticals has a twelve month low of $0.95 and a twelve month high of $7.54.

Analysts Set New Price Targets

Several research firms have recently commented on ACXP. HC Wainwright reaffirmed a “buy” rating on shares of Acurx Pharmaceuticals in a report on Tuesday, September 29th. Weiss Ratings reissued a “sell (e+)” rating on shares of Acurx Pharmaceuticals in a report on Thursday, October 15th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold”.

Acurx Pharmaceuticals Company Profile

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) is a clinical-stage biopharmaceutical company focused on developing novel antibiotics for serious bacterial infections. The company’s research is centered on therapies designed to address pathogens that are resistant to existing treatments. Acurx’s lead product candidate is ibezapolstat, also known as ACX-375, an investigational oral antibiotic being developed for the treatment of Clostridioides difficile infection, commonly known as C. difficile infection.